Select: All | None

Select: All | None

Select: All | None

Featured Opportunity

Flexible-Base Electrode Array and Method of Manufacture

University of Alberta

-
Featured Opportunity

Small molecule therapeutic for multiple sclerosis (MS)

Centre for Addiction and Mental Health

Our scientists have developed a novel series of peptide and small molecule therapeutics for the treatment of multiple sclerosis (MS). This development program targets neuroprotective mechanisms through a highly specific interaction in GluA2/GAPDH signalling. It has been demonstrated that both these peptide and lead small molecules are highly effective in animal models of MS. In addition, these therapeutics promote neuronal and oligodendrocyte survival. Agents that selectively inhibit highly...

METHODS, COMPOUNDS AND COMPOSITIONS FOR MODULATING BLOOD BRAIN BARRIER INTEGRITY AND RE-MYELINATION

University Health Network

Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as methods and compositions for promoting re-myelination and preventing de-myelination. Compositions include RGMa, soluble RGMa, and functional fragments and variants thereof, RGMc, soluble RGMc, and functional fragments and variants thereof, and Neogenin peptides...

ENDOGENOUS RETROVIRUS-K (ERVK) ENCODES AN ALTERNATE ENVELOPE PROTEIN

University of Manitoba

The present disclosure relates to an endogenous Retrovirus K protein (ERVK) with an alternative envelope protein titled CTXLP. Said CTXLP peptide is represented by the sequences set forth in SEQ ID NO: 1. Additionally, antibodies that specifically recognize the epitope(s) set forth in SEQ ID NO:1 are and methods of use thereof and kits comprising the peptide set forth in SEQ ID NO:1 are also included in the present disclosure.

METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS

University of Alberta

Compounds capable of activating a neuronal heteromeric nicotinic acetylcholine receptor are provided and can be administered in the form of pharmaceutical compositions of the like. Methods for using the compounds for treating, preventing, or ameliorating respiratory depression and overdose induced by an opioid, or other cause of respiratory depression are also provided. Methods of inducing analgesia, anesthesia, or sedation in a subject, while simultaneously treating, preventing, or...

AGENTS DIRECTED AGAINST A CIS RGMA/NEOGENIN INTERACTION OR LIPID RAFTS AND USE OF THE SAME IN METHODS OF TREATMENT

University Health Network

Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject....

PEPTIDE DIRECTED PROTEIN KNOCKDOWN

University of British Columbia

In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for...

PERFLUOROKETONE COMPOUNDS AND USES THEREOF

McGill University, Regents of the University of California, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITY OF ATHENS

Novel perfluoroketone compounds of formula [I] and [Ia] are described Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and / or inflammatory conditions, such as demeyelmatmg (e.g., multiple sclerosis) and neural injury (e.g., spinal cord injury).

PHOSPHOLIPASE A2 INHIBITORS AND THEIR USE IN TREATING NEUROLOGICAL INJURY AND DISEASE

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Phospholipase A2 (PLA2) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA calcium independent PLA2 (iPLA2) and/or Group V secreted PLA2 (sPLA2). Pharmaceutical compositions of compounds having cPLA2 inhibitory activity (but not iPLA2 or...

To help us serve you better,

please tell us what sector you work in: